🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. LOSARTAN

    Istituto Gentili S.r.l.

    Osteogenesis Imperfecta

    phase 2 small molecule active

    1 trial

  2. LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001

    Novartis Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  3. LUMYKRAS 120 mg film-coated tablets

    The George Institute

    locally-advanced and unresectable or metastatic NSCLC with KRAS G12C

    phase 2 small molecule active

    1 trial

  4. LX2020

    Lexeo Therapeutics

    Arrhythmogenic Cardiomyopathy

    phase 2 gene therapy active

    1 trial

  5. LX6171 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Age-Related Memory Disorders

    phase 2 small molecule completed

    1 trial

  6. LY3871801

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  7. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  8. Lacutamab

    Lacuna Pharma Pty Ltd

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    phase 2 small molecule active

    1 trial

  9. Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Lenalidomide and Gemcitabine (Dose level 11)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  11. Lenalidomide combined with G-CHOP (LO CHOP)

    The First People's Hospital of Lianyungang

    DLBCL - Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  12. Lenvatinib, Belzutifan, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Patients with localized renal cell carcinoma

    phase 2 small molecule active

    1 trial

  13. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    The George Institute

    Resectable mucosal melanomas

    phase 2 small molecule active

    1 trial

  14. Lenvatinib, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830, ETOPOSIDE, Lenvatinib, CISPLATIN, boserolimab, CARBOPLATIN

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  15. Lenvatinib, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

  16. Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, medoxa 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery

    phase 2 small molecule active

    1 trial

  17. Leuprolide acetate

    Voyager Therapeutics

    Alzheimer Disease

    phase 2 small molecule completed

    2 trials

  18. Levact 2,5 mg/ml, polvo para concentrado para solución para perfusión., Beneflur10 mg comprimidos recubiertos con película, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión, HSP-CAR19M

    The George Institute

    Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma

    phase 2 small molecule active

    1 trial

  19. Lidocaína B. Braun 20 mg/ml solución inyectable, Suero Fisiológico Braun 0,9% disolvente para uso parenteral Cloruro de sodio

    The George Institute

    headache pain related to SAH, Spontaneous subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  20. Linezolid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Meningeal

    phase 2 small molecule completed

    1 trial

  21. Linvoseltamab

    Regeneron UK Limited

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  22. Linvoseltamab

    Regeneron UK Limited

    Monoclonal Gammopathy of Undetermined Significance (MGUS)

    phase 2 small molecule active

    1 trial

  23. Linvoseltamab

    Regeneron UK Limited

    Relapsed/Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  24. Linvoseltamab

    Regeneron UK Limited

    Recurrent Multiple Myeloma

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources